Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.
Shouse G, Chen C, Muir A, Popplewell L, Siddiqi T, Zain J, Herrera AF, Danilova O, Roleder C, Wang L, Spurgeon SEF, Kittai AS, Chen L, Xia Z, Davids MS, Danilov AV. Shouse G, et al. Among authors: popplewell l. Haematologica. 2025 Jul 3. doi: 10.3324/haematol.2024.286945. Online ahead of print. Haematologica. 2025. PMID: 40605718 Free article.
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
Godfrey J, Mei M, Chen L, Song JY, Bedell V, Budde E, Armenian S, Puverel S, Nikolaenko L, Chen R, Daniels S, Kennedy N, Peters L, Rosen ST, Forman SJ, Popplewell LL, Kwak LW, Herrera AF. Godfrey J, et al. Among authors: popplewell ll. Haematologica. 2024 Feb 1;109(2):533-542. doi: 10.3324/haematol.2023.283002. Haematologica. 2024. PMID: 37470137 Free PMC article. Clinical Trial.
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.
Othman T, Frankel P, Allen P, Popplewell LL, Shouse G, Siddiqi T, Danilov AV, Ruel N, Daniels S, Peters L, Khoo S, Rosen ST, Sharon E, Villalona-Calero M, Ruel C, Tuscano J, Herrera AF. Othman T, et al. Among authors: popplewell ll. Haematologica. 2025 Jan 1;110(1):142-152. doi: 10.3324/haematol.2024.285185. Haematologica. 2025. PMID: 39021209 Free PMC article. Clinical Trial.
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M, Nathwani N, Htut M, Nademanee A, Forman SJ, Kirschbaum M. Chen R, et al. Among authors: popplewell l. Haematologica. 2015 Mar;100(3):357-62. doi: 10.3324/haematol.2014.117473. Epub 2015 Jan 16. Haematologica. 2015. PMID: 25596263 Free PMC article. Clinical Trial.
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KJ, Armenian S, Nwangwu M, Lee PP, Zain J, Nikolaenko L, Popplewell L, Nademanee A, Chaudhry A, Rosen S, Kwak L, Forman SJ, Herrera AF. Mei MG, et al. Among authors: popplewell l. Blood. 2022 Jun 23;139(25):3605-3616. doi: 10.1182/blood.2022015423. Blood. 2022. PMID: 35316328 Free PMC article. Clinical Trial.
PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Thiruvengadam SK, Mei MG, Godfrey J, Siddiqi T, Salhotra A, Chen R, Smith E, Popplewell LL, Herrera AF. Thiruvengadam SK, et al. Among authors: popplewell ll. Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):e893-e897. doi: 10.1016/j.clml.2022.06.004. Epub 2022 Jun 6. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35778267
Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
Chen RW, Palmer JM, Tomassetti S, Popplewell LL, Alluin J, Chomchan P, Nademanee AP, Siddiqi T, Tsai NC, Chen L, Zuo F, Abary R, Cai JL, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LW, Holmberg LA. Chen RW, et al. Among authors: popplewell ll. J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3. J Hematol Oncol. 2018. PMID: 29954415 Free PMC article. Clinical Trial.
Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy.
Lee K, Iukuridze A, He T, Bosworth A, Lindenfeld L, Teh JB, Echevarria M, Albanese S, Atencio L, Bhandari R, Wong FL, Artz AS, Siddiqi T, Nikolaenko L, Zain J, Mei M, Shouse G, Popplewell LL, Herrera AF, Budde LE, Forman SJ, Armenian SH. Lee K, et al. Among authors: popplewell ll. J Natl Compr Canc Netw. 2023 Apr;21(4):373-382.e1. doi: 10.6004/jnccn.2022.7100. J Natl Compr Canc Netw. 2023. PMID: 37015335
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Mei M, Chen L, Godfrey J, Song J, Egelston C, Puverel S, Budde LE, Armenian S, Nikolaenko L, Nwangwu M, Guo W, Gao L, Lee P, Chen R, Daniels S, Kennedy N, Peters L, Zain J, Rosen S, Forman S, Popplewell L, Kwak L, Herrera AF. Mei M, et al. Among authors: popplewell l. Blood. 2023 Oct 19;142(16):1359-1370. doi: 10.1182/blood.2023020485. Blood. 2023. PMID: 37339586 Free PMC article.
Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma.
Thiruvengadam SK, Mei MG, Chen L, Puverel S, Chen R, Popplewell LL, Nikolaenko L, Peters L, Armenian S, Kwak LW, Rosen ST, Forman SJ, Herrera AF. Thiruvengadam SK, et al. Among authors: popplewell ll. Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):724-731.e1. doi: 10.1016/j.clml.2024.05.017. Epub 2024 Jun 15. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39043499 Clinical Trial.
173 results